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Thisstudywasconductedtoassesstheoccurrenceoffracturesinsolid-organtransplantrecipients.Methods. Medical record review
and surveys were performed. Patients received less than 6 months of glucocorticoids. Results. Of 351 transplant patients, 175
patients provided fracture information, with 48 (27.4%) having fractured since transplant (2–6 years). Transplants included 19
kidney/liver (50% male), 47 kidney/pancreas (53% male), 92 liver (65% male), and 17 pancreas transplants (41% male). Age at
transplant was 50.8 ± 10.3 years. Fractures were equally seen across both genders and transplant types. Calcium supplementation
(n = 94) and bisphosphonate therapy (n = 52) were observed, and an association with a lower risk of fractures was noted for
bisphosphonate users (OR = 0.45 95% C.I. 0.24, 0.85). Fracture location included 8 (16.7%) foot, 12 (25.0%) vertebral, 3 (6.3%)
hand, 2 (4.2%) humerus, 5 (10.4%) wrist, 10 (20.8%) fractures at other sites, and 7 (14.6%) multiple fractures. The estimated
relative risk of fracture was nearly seventeen-times higher in male liver transplant recipients ages 45–64 years compared with the
general malepopulation,and comparabletofractureratesonconventional immunosuppressantregimens. Conclusion.Weidentify
a high frequency of fractures in transplant recipients despite limited glucocorticoid use.
1.Introduction
Within the past 3 decades, organ transplantation has become
an established therapy for end-stage diseases of the kidney,
liver, and lung. Survival after solid-organ transplantation
has improved markedly mainly because of the addition of
calcineurininhibitors,cyclosporineA(CsA),andtacrolimus,
to posttransplantation immunosuppressive regimens. With
improved survival has come a greater appreciation of com-
plications such as osteoporosis and fractures that negatively
inﬂuence patients’ quality of life. The pathogenesis of
transplantation osteoporosis is complex and incompletely
understood. It is probably related to a combination of nox-
ious eﬀects to the skeleton that occur both before and after
organtransplantation.Cardiac,kidney,lung,andliverfailure
each have unique pathophysiologies that inﬂuence bone
and mineral metabolism before transplantation. Additional
factors such as aging, nutritional deﬁciencies, immobility,
diabetes mellitus, tobacco, and alcohol may aﬀect the
skeletons of these transplant recipients before and after
transplantation. In the posttransplant period, patients are
then subjected to a drug regimen that usually includes
high doses of glucocorticoids, the most common cause of
secondary osteoporosis. Glucocorticoids are prescribed in
combination with other immunosuppressive agents, such
as calcineurin inhibitors (cyclosporine A or tacrolimus),
rapamycin, mycophenylate mofetil, and azathioprine. Of
theseagents,bothcyclosporineAandtacrolimusarethought
to have speciﬁc adverse eﬀects upon skeletal integrity. It is
thought that the independent and interconnected skeletal2 Journal of Osteoporosis
eﬀects of glucocorticoids and calcineurin inhibitors lead to
a form of bone disease characterized by rapid bone loss and
high rates of fractures [1–6].
While most transplant centers have used triple therapy
consisting of a calcineurin-inhibitor (CNI), an antimetabo-
lite, and steroids as induction and maintenance regimens,
steroid sparing regimens have been developed due to the
concern in the transplant community about the importance
of steroid-related morbidity [7, 8]. The purpose of this study
was, therefore, to evaluate whether glucocorticoid-sparing
immunesuppressive regimens are associated with a reduced
riskoffractures.Ourpriorworkhasshownthatconventional
immunosuppressantregimenswereassociatedwitha13-fold
higher risk of fracture than age- and gender-matched rates
form a nationally representative sample (National Health
Interview Survey).
2.MaterialsandMethods
2.1. Patients. The Kovler Transplant Center at Northwestern
University is located at Northwestern Memorial Hospital.
An extensive clinical database is maintained at Northwestern
Memorial Hospital. The status of all patients in the database
is maintained as part of the regular posttransplantation care
at the respective hospitals. The Institutional Review Board
approved this study and all participants provided informed
consent.
Inclusion. 18 years of age and older recipients of solid-
organ transplants between January 1, 2001 and December
31, 2007, survivals for at least 2 years after transplant. Use of
glucocorticoids limited to the initial 6 months of immuno-
suppressive regimen.
Exclusion. prolonged glucocorticoid therapy, inability to
provide informed consent, fractures of digits or toes, and
skull fractures. The cohort for this study includes 351
patients who received pancreas, kidney-pancreas, and liver
transplants and survived. Adequate fracture information was
obtained in 175 subjects. There were 92 liver, 47 kidney-
pancreas, 19 kidney-liver, and 17 pancreas transplants pre-
formed and evaluable during the study interval. Kidney-only
transplants and cardiac transplants were excluded due to
prolonged glucocorticoid use.
2.2. Fracture Ascertainment and Veriﬁcation. Information in
symptomatic incident fractures was obtained retrospectively
in the organ transplant cohort. All patients were contacted
by telephone (88%) or at the clinic visit (12%) and
queried about fracture occurrence since the transplant. All
fractures identiﬁed were veriﬁed by review of the medical
record for formal radiographic reports or other relevant
documentation. Asymptomatic fractures not located in the
thoracic spine/rib cage (visualized on chest X-ray) may have
beenmissed becauseroutinethoracic andlumbar spine ﬁlms
were not obtained for spinal morphometry. Fractures of the
face and digits were excluded from analysis.
2.3. Data Analysis. Descriptive statistics such as mean ±
SD (standard deviation) were used to summarize patient
characteristics for continuous variables whereas frequency
and percentage were used for categorical variables. Incidence
rate per person-year of fracture was calculated, using the
observed fracture frequency in this study cohort as the
numerator, and a product of the individuals at risk and the
time units as the denominator. The time units were deﬁned
as the years since the transplant till whatever happened ﬁrst
during the followup, fracture date, or the interview date.
All interviews were conducted between July 1, 2007 and
December 31, 2009. Overall person-year fracture incidence
rate was computed, as well the age- and gender-speciﬁc
person-year fracture incidence rate. Age was also stratiﬁed
as <18, 18–24, 25–44, 45–64, and 65–69, according to 1994
NHIS grouping. Organ-, age-, and gender-speciﬁc numbers
and rates, and person-years of observation were calculated.
Weighted age- and gender-speciﬁc fracture rates from 1994
NHIS (National Health Interview Survey) were applied to
the number of person-years of observation for each organ-
speciﬁc age and gender category of transplant patients
to calculate an expected number of fractures. The ratio
(expressed as an estimated relative risk) of observed and
expected number of fractures was used to compare fracture
of transplant patients to that of the national sample of the
1994 NHIS.
A Chi-square or Fisher’s exact test was used to assess the
association between categorical variables (i.e., gender) and
the occurrence of fracture. A two-sample t-test was used
to assess the diﬀerence between fractured and nonfractured
subjects, with respect to continuous variables (i.e., age at
transplant). Time to event analysis was applied to estimate
the average time to fracture after transplant among organ
transplant recipients. Kaplan-Meier plot was used to depict
the time to fracture diﬀerence between male and female,
between age at transplant ≥45 and <45 patients, and among
organ transplant types. Log-rank test was used to determine
the P values. A two-sided signiﬁcance level 0.05 was used.
Data were stored in excel format, and the statistical analysis
w a sc a r r i e do u tu s i n gS A S9 . 1 .
3. Results
The speciﬁc patient characteristics stratiﬁed by type of organ
transplant are shown in Table 1. Of 298 transplant patients
(Jan 2001–Dec 2007), 175 patients provided fracture infor-
mation, with 48 (59%) having fractured since transplant
(2–6 years). Nonrespondents were similar in demographic
characteristics as well as comorbidities. Calcium supple-
mentation (n = 94) and bisphosphonate therapy (n =
52) were observed and an association with a lower risk of
fractures was noted for bisphosphonate users (OR 0.45 95%
C.I. 0.24, 0.85). Transplants included 19 kidney/liver (50%
male), 47 kidney/pancreas (53% male), 92 liver (65% male),
and 17 pancreas transplants (41% male). Age at transplant
was similar (P = 0.146) in fracture (47.8 ± 11.3y e a r s )
and nonfracture groups (50.4 ± 10.0yrs). Fractures were
equally seen (P = 0.224) in both genders (23 of 71 female
(32.4%)and25of104male(24.0%)).Fractureswereequally
distributed (P = 0.582) across all transplant types (15.8%,
29.8%, 27.2%, and 35.3%, resp.). Fracture location includedJournal of Osteoporosis 3
Table 1: Characteristics of organ transplant recipients and patients with fractures.
Patient features Kidney/liver Kidney/pancreas Liver Pancreas
Number of patients 19 47 92 17
Gender (% female) 52.6 46.8 35 58.8
Age at transplant in years (mean ± SD) (n)5 4 .9 ±7.54 3 .9 ±8.25 3 .2 ±10.34 1 .1 ±7.3
Number with fractures 4 15 22 7
Men 1/9 7/25 16/60 1/7
11% 28% 27% 14%
All women 3/10 8/22 6/32 6/10
30% 32% 19% 60%
Postmenopausal women∗∗ 2/10 5/22 5/22 0/1
20% 23% 23% 0%
∗∗Menopause assumed if age at fracture ≥50 years.
Table 2: Age- and gender-speciﬁc fracture incidence rates in all transplant recipients.
Women Men
Age in years Person-years
at risk
Observed
number of
fractures
Expected
number of
fracture
Estimated
relative risk
Person-years
at risk
Observed
number of
fractures
Expected
number of
fractures
Estimated
relative risk
<1 8 00 — — 00 — —
18–24 2.8 1 — — 0 0 — —
25–44 106.1 6 0.33 18.2 127.0 9 0.83 10.9
45–64 155.1 16 0.47 34.4 280.3 12 0.81 14.8
65–69 14.1 0 0.06 0 31.1 3 0.09 0
Table 3: Age and gender speciﬁc fracture incidence rates in the US
population. National Center for Health Statistics, National Health
Interview Survey (NHIS) 1994.
Age in Years Women Men
<18 5.9 10.7
18–24 1.8 10.3
25–44 3.1 6.5
45–64 3.0 2.9
65–69 4.6 2.8
8 (17.5%) foot (metatarsal), 8 (16.7%) vertebral, 12 (25.0%)
vertebral, (6.25%) hand 3, 2 (4.2%) humerus, 5 (10.4%)
wrist fractures, 10 (20.8%) occurred at other sites, and 7
(14.6%) occurred at multiple sites (Figure 1). Of the 25
men with fractures, the incidence of fractures was 0.065 per
person-year among the 733.8 person-years of observation.
Patient characteristics were stratiﬁed by type of organ
transplant(Table1).Four(21%)ofthe19kidney-livertrans-
plant recipients had symptomatic initial fractures during
the 76.9 person-years of observation for a crude fracture
rate of 0.039 per year of observation. The mean age at
the time of the initial symptomatic fracture was 56.5 ±
9.2 years (median: 58; range: 47–65), and the mean time
from transplant to initial fracture was 54.1 ± 18.8 months
(median: 54; range: 41–67). Both axial (n = 2) and limb
(n = 1) fractures occurred in this small group.
Fifteen of 47 kidney-pancreas (32%) recipients had their
initial symptomatic fracture during the 207.1 person-years
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Figure 1: Type of fracture by type of solid-organ transplant.
of observation for a crude fracture rate of 0.068 per year of
observation. The mean age at the time of initial fracture was
48.3 ± 9.3 years, (median: 50; range: 32–63), and the mean
number of months from transplant to initial fracture was
51.0 ± 23.2 months (median: 59; range: 5–80). The most
common site of fracture in this group was the foot, and
occurred equally in males and females 28.0% versus 31.8%,
respectively. Five axial (rib and spine) fractures occurred
compared with 7 limb fractures in this group as compared
to 15 limb fractures. Two of the 3 patients who reported
multiple fractures were women.4 Journal of Osteoporosis
Table 4: Age- and gender-speciﬁc fracture incidence rates in kidney/liver transplant recipients.
Women Men
Age in years Person-years
at risk
Observed
number of
fractures
Expected
number of
fractures
Estimated
relative risk
Person-years
at risk
Observed
number of
fractures
Expected
number of
fractures
Estimated
relative risk
<1 8 00 — — 00 — —
18–24 0 0 — — 0 0 — —
25–44 7.0 0 0.02 0 5.5 0 0.04 0
45–64 30.1 2 0.09 22.1 28.8 2 0.08 12.0
65–69 5.3 0 0.02 0 0 0 — —
Table 5: Age- and gender-speciﬁc fracture incidence rates in kidney/pancreas transplant recipients.
Women Men
Age in years Person-years
at risk
Observed
number of
fractures
Expected
number of
fractures
Estimated
relative risk
Person-years
at risk
Observed
number of
fractures
Expected
number of
fractures
Estimated
relative risk
<1 8 0 0 —— 0 0 ——
18–24 0 0 — — 0 0 — —
25–44 44.5 2 0.14 7.2 62.3 4 0.40 9.9
45–64 43.8 6 0.13 45.7 52.4 4 0.15 26.2
65–69 0 0 — — 0 0 — —
Twenty-two (24%) of 92 liver transplant recipients had
fractures during the 383.3 person-years of observation, for
a crude fracture rate of 0.065 per year of observation.
The mean age at the time of initial symptomatic fracture
was 54.4 ± 12.2 years (median: 57; range: 25–71), and
the mean number of months from transplant 36.0 ± 28.9
months (median: 30; range: 3–86). Nine axial (vertebral and
hip) fractures occurred compared with 18 limb fractures.
Four patients receiving liver transplants sustained multiple
fractures.
Seven (41%) of the 17 pancreas transplant recipients
had fractures during the 66.5 person-years of observation
f o rac r u d ef r a c t u r er a t eo f0 . 0 9 0p e ry e a ro fo b s e r v a t i o n .
The mean age at the time of initial symptomatic fracture
was 40.6 ± 6.5 years (median: 42; range: 31–50), and the
mean number of months from transplant to initial fracture
was 41.7 ± 22.1 months (median: 42; range; 26–57). All 3
fracturesin this group were limb fractures(1 wrist and 2 foot
(metatarsal)), and none sustained multiple fractures.
Age- and gender-speciﬁc fracture incidence rates repre-
sentative of the US civilian, noninstitutionalized population
from the 1994 NHIS are shown in Tables 2, 3, 4, 5, 6,a n d7.
The comparison of age- and gender-speciﬁc incidence rates
for initial symptomatic fractures in solid-organ transplant
recipients and the US population were shown in Tables 3, 4,
5, 6,a n d7.
The male liver transplant recipients aged 45–64 years at
the Kovler Transplant Center cohort had 100 person-years of
observation.Theestimatedrelativeriskoffracturewasnearly
seventeen-times higher in male liver transplant recipients
ages 45–64 years compared with the general male population
of those age groups.
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Figure 2: Proportion of fracture among all patients over time.
For those 175 transplant recipients who provided valid
fracture data (yes or no), the median followup was 4.46
years (range: 0–7.93 years), 75% nonfracture time was 5.04
years (95% conﬁdence interval: 4.08–5.37 years). Figure 2
demonstrated that among those 175 transplant recipients
about 5% sustained fracture within the ﬁrst 12 months while
by 5 years about 25% of transplant recipients have sustained
a fracture. The time to fracture was not diﬀerent between
females and males, neither between patients with age <45
and ≥45yearsofageattimeoftransplant,norbetweenorgan
transplant types.Journal of Osteoporosis 5
Table 6: Age- and gender-speciﬁc fracture incidence rates in liver transplant recipients.
Women Men
Age in years Person-years
at risk
Observed
number of
fractures
Expected
number of
fractures
Estimated
relative risk
Person-years
at risk
Observed
number of
fractures
Expected
number of
fractures
Estimated
relative risk
<1 8 0 0 —— 0 0 ——
18–24 2.8 1 0.005 201.5 0 0 — —
25–44 33.2 1 0.10 9.7 33.3 4 0.22 18.5
45–64 75.3 7 0.23 31.0 189.2 6 0.55 16.4
65–69 8.8 0 0.04 0 31.1 3 0.09 34.5
Table 7: Age- and gender-speciﬁc fracture incidence rates in pancreas transplant recipients.
Women Men
Age in years Person-years
at risk
Observed
number of
fractures
Expected
number of
fractures
Estimated
relative risk
Person-years
at risk
Observed
number of
fractures
Expected
number of
fracture
Estimated
relative risk
<1 8 0 0 —— 0 0 ——
18–24 0 0 — — 0 0 — —
25–44 25.0 4 0.08 51.7 25.8 2 0.17 6
45–64 5.9 1 0.02 56.5 9.9 0 0.03 0
65–69 0 0 — — 0 0 — —
4. Discussion
This study is the ﬁrst to quantify the magnitude of excess
fractures occurring in solid-organ transplant recipients
(liver) on glucocorticoid-sparing immuno-suppressive reg-
imens. An elevated fracture risk (17-fold increased risk
of fractures) was identiﬁed, in fact, the fracture incidence
was similar to our prior studies of transplant recipients on
conventional antirejection regimens [9]. As survival after
organ transplantation has improved, skeletal complications
are becoming increasingly troubling, with some studies
showing fracture incidence of 20–40% post transplant [10–
12]. Immuno-suppressive regimens with limited glucocor-
ticoid use have been developed in an attempt to min-
imize adverse events. Prior studies have assessed kidney
transplants, showing that glucocorticoid-free protocols have
resulted in less bone loss, although fractures have not
been reported as primary outcomes [13–15]. Glucocorti-
coids and calcineurin inhibitors have speciﬁc adverse eﬀects
on the skeleton [16–18], and have been associated with
increased risk for fracture. Glucocorticoids contribute to
posttransplant bone loss, especially the rapid loss that occurs
in the ﬁrst 6–12 months, by inhibiting bone formation.
Thus, organ transplantation has been revolutionized in the
era since the routine use of immune suppressive therapy
with glucocorticoids, calcineurin inhibitors (cyclosporine
A or tacrolimus), and either mycophenolate mofetil or
azathioprine.
Post transplantation osteoporosis is a complex and
multifactorial disease with preexisting bone loss associated
with end-stage organ failure, immobility, aging, high-dose
glucocorticoid use, and immune suppressant therapy having
been implicated. End-stage kidney or liver disease, and
congestive heart failure are associated with low bone mineral
density, fractures, and abnormalities of mineral metabolism
[19–23] .M e t a b o l i cd i s t u r b a n c e ss u c ha sa b n o r m a l i t i e si n
calcium, phosphorus, and parathyroid hormone persist for
many months or years following kidney transplantation
[24]. Diabetes mellitus, a common cause for pancreas and
kidney transplants, results in alterations in bone metabolism
and fractures [19, 25–27]. Hypogonadism common in older
males has been associated with bone loss and fractures [28–
30]. Immobility due to end-stage organ disease has profound
eﬀect on bone metabolism [31].
Additionally, we identiﬁed that calcium supplementa-
tion and vitamin D was common in transplant recipients,
but failed to reduce fracture risk. Bisphosphonate therapy
however, was identiﬁed as being associated with a reduc-
tion in fracture risk. These preliminary ﬁndings suggest
important treatment options in transplant candidates with
suitable kidney function such as CKD stage 2-3 (GFR >
35cc/min/1.73m2).
Our data on four self-reported symptomatic fractures in
19liver-kidneytransplantrecipientsrepresentsbothgenders.
Symptomatic axial fractures were less frequently reported
thanlimbfractures.Thereisapaucityofstudiesassessingthe
incidence of fractures in these transplant recipients. All four
fractures occurred in patients with pretransplant chronic
hepatitis, none of these patients had diabetes mellitus. We
reported on 15 fractures occurring in 47 kidney-pancreas
recipients, all of whom had diabetes mellitus and end-stage
kidney disease. In the kidney pancreas transplant recipients6 Journal of Osteoporosis
followed for a mean time of 6.3 years we noted more limb
than axial fractures. Our ﬁndings conﬁrm the high incidence
of fractures of 20–45% in prior studies [19, 32–34]. Diabetes
mellitus results in low bone formation bone disease, with
consequent fractures [27, 35, 36].
We described 22 symptomatic fractures in 92 liver
transplant recipients, this cohort was followed for a mean
of 6 years, the crude fracture rate was 0.063 per year. These
data are comparable to the frequency of postliver-transplant
fractures reported in other studies ranging from 20–40%
[10–12]. Up to 21% of patient who receive a liver transplant
sustain a fracture within the ﬁrst two years [37]. Thus this
data demonstrate that rate of fracture on glucocorticoid-
sparing regimen remains unchanged. Fractures were most
common in patients with hepatocellular carcinoma (3/3,
100%), than in patients with chronic hepatitis (13/49, 26%)
or alcoholic-induced cirrhosis (2/9, 22%).
We also reported on seven fractures in 17 pancreas
transplants with diabetes and followed for a mean of 4 years.
The most common site aﬀected was the foot. Patients who
received kidney pancreas and pancreas transplants were dia-
betic and 10 years younger than other solid-organ transplant
recipients. In all cases, fractures were limb fractures.
Calcineurin inhibitors have allowed for improved sur-
vival and reductions in glucocorticoid therapy in trans-
plantation. However, the calcineurin inhibitors, cyclosporine
(CsA), and tacrolimus (FK506) have also been implicated
in posttransplant bone disease. These drugs stimulate loss
of bone mass independent of glucocorticoid therapy, with
high-turnover bone metabolism noted in rat models [38–
40]. Speciﬁcally, CsA administration has resulted in marked
increases in bone resorption and formation as well as greater
losses of trabecular bone [38–40]. Furthermore, its direct
eﬀects on calcineurin genes expressed in osteoclasts may
aﬀect bone turnover [41, 42]. FK506 has also been shown
in rat models to cause loss of trabecular bone volume in
rats [38–40]. Comparison of the two drugs in rat models
has demonstrated more severe bone loss with the use of
CsA than FK506. In liver transplant patients [43], there is
a more favorable long-term eﬀect on bone mass evolution
with the use of FK506 up to 2 years posttransplantation [44].
Both have been noted to cause signiﬁcant bone resorption in
kidney transplant recipients [17]. However, FK506 has been
noted to protect bone mineral density better than CsA when
both have been administered with combined steroid therapy
over 1 year [45]. Less is understood of the eﬀects of other
immunosuppressive agents on bone loss. Few studies have
evaluated the eﬀects of mycophenolate mofetil (MMF) and
sirolimus on bone metabolism [46]. In rat models, short-
term use of MMF did not result in decreased bone volume
[46,47].Inhumans,comparisonofCsAtosirolimusresulted
in less bone turnover and less bone resorption with sirolimus
[47] in the short term. Longer-term data is warranted.
There are several limitations with this analysis as com-
parisons between the fracture rates in the transplant cohort
and the NHIS data should be interpreted with caution. First,
the NHIS data includes self-reported fractures that were not
veriﬁed. We used a more stringent case ﬁnding procedure in
the transplant cohort as we veriﬁed the patient’s self-report
of fracture. Thus, our observed number of fractures is more
conservative than the NHIS data. Second, the number of
person-years of observation in some of our strata are small,
especially for kidney pancreas and kidney-liver recipients.
Thus,theexpectednumberoffracturesaresmall,resultingin
relative risk estimates that are unstable and liable to inﬂation
fromaverysmallnumberofevents.Thus,wedidnotusetest
of signiﬁcance for these results. Fractures rates for patients
included only the initial posttransplant fracture while some
patients experienced more than one fracture. Therefore,
the number of fracture events in the transplant cohort
represent the lowest estimate of the problem. In the strata
with at least 100 person-years, we determined that fractures
in transplant patients were increased nearly seventeen-fold
compared with expected numbers from national data. The
frequency of fractures in this transplant cohort clearly
representthelowerboundaryoftheproblembecauseroutine
surveillance for asymptomatic vertebral fractures was not
performed. Nevertheless, using our conservative estimate
from the occurrence of symptomatic fractures, these data
demonstrate the magnitude of this excess risk.
There is limited information in medical records about
potential risk factors for increased fracture rate observed
in this study. Previous studies of those risk factors reveal
inconsistent ﬁndings. For kidney transplant patients, risk
factors associated with fracture included low BMD, prior
parathyroidectomy, higher glucocorticoid use, and longer
interval between transplant and fracture [48]. A population-
based study showed that age and diabetic nephropathy
were independent predictors of fracture risk while higher
activity status was protective [49]. Future well characterized
studies will allow better deﬁnition of speciﬁc risk factors for
transplant-related fractures in this heterogeneous cohort.
Patients with kidney/pancreas and pancreas transplan-
tation appear to be at higher risk of fracture. Diabetics are
predisposed to low bone turnover bone disease, neuropathy,
and osteopenia. Factors uniquely associated with osteope-
nia in diabetics include chronic hypocalcemia, insulin
deﬁciency, hypomagnesemia, relative hypoparathyroidism,
negative protein balance, immobility, hypogonadism, and
metabolic acidosis [19, 27, 35, 36].
In liver transplant recipients, initial BMD, interval
change in BMD, menopause, primary biliary cirrhosis, long-
term glucocorticoid use, calcineurin inhibitors, underlying
pretransplant disease severity, multiple fractures, and pre-
transplant fracture have been identiﬁed as risk factors for
fractures [10, 22, 37, 50].
5. Conclusion
This study is the ﬁrst to quantify the magnitude of excess
fractures occurring in solid-organ transplant recipients on
glucocorticoid-sparing immuno-suppressive regimens. Liver
transplantrecipientshavea17-foldincreasedriskoffractures
as compared to age- and gender-matched controls. Addi-
tional research must be conducted to clarify pathogenesis
of bone loss and fractures and the development of suitable
preventive strategies.Journal of Osteoporosis 7
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